Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis
NCT ID: NCT01665235
Last Updated: 2012-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2012-08-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
amlodipine
The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
Amlodipine
The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
Aspirin or Clopidogrel
aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
Atorvastatin
Atorvastatin 10 - 40mg / d ( statin therapy)
ACEI / ARB
ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
ACEI / ARB
ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
Aspirin or Clopidogrel
aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
Atorvastatin
Atorvastatin 10 - 40mg / d ( statin therapy)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlodipine
The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
ACEI / ARB
ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
Aspirin or Clopidogrel
aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
Atorvastatin
Atorvastatin 10 - 40mg / d ( statin therapy)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with intracranial artery stenosis in ischemic stroke
* the diagnosis of ischemic cerebrovascular disease are in line with the diagnostic criteria developed by the Chinese Medical Association Fourth National Cerebrovascular Disease Conference
* the patient admitted to hospital receive at least one examination like cranial MRI + DWI, MRA and TCD examination, clearly associated with intracranial arterial stenosis
* MRS score ≤ 3 points
Exclusion Criteria
* associated with significant emotional disorders, cognitive impairment or other mental disorders can not be partners
* severe occlusion of Unilateral intracranial arteries ( over 90 % ) or bilateral stenosis more than 70%
* With extracranial artery stenosis, especially carotid and vertebral artery stenosis .
* patients with extracranial artery stenosis or patients previously done neck or intracranial artery balloon dilation , stent forming surgery or carotid endarterectomy
* Incomplete clinical data collection in patients
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shi Guowen
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guowen Shi, MD
Role: PRINCIPAL_INVESTIGATOR
RenJi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RenJi Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RenJiH-20120804
Identifier Type: -
Identifier Source: org_study_id